ZIM Labs to list on National Stock Exchange on November 25

ZIM Laboratories Limited, already listed on the BSE since June 2018.

November 24, 2022 9:16 IST | India Infoline News Service
A pharmaceutical company, ZIM Laboratories Ltd has annnounced that it is planning to get listed on the National Stock Exchange on November 25, 2022.

ZIM Laboratories is already listed on the BSE since June 2018 and plans to extend its listing to the NSE now.

Notably, as on date, it has provided over 85% return to its investors from the listing price.

According to September 2022 shareholding pattern available on BSE, the company’s promoters own 33.26% stake in the company of which, Dr. Anwar Daud, Chairman and Managing Director owns 27.37% stake and Mathew Cyriac, Executive Chairman of Florintree Advisors as an investor owns 21.86% stake.

With a clear focus on growing its R&D capabilities, the company has been regularly investing in R&D and in H1FY23 has invested 7.3% of its total operating income into research initiatives.

Over the last 2 years (FY20 to FY22), Operating Income, EBITDA and PAT for the company has surged at a CAGR of 9.6%, 29% and 110% respectively. For H1FY23, Operating Income grew 35.6% to Rs192 crore against Rs141 crore for the same period last year (H1FY22).

EBITDA for H1FY23 rose to Rs26.8 crore Vs Rs17.6 crore in H1 FY22 and Net Profit was at Rs10.6 crore in H1 FY23 Vs Rs3.45 crore in H1 FY22. Further, Borrowings has also reduced from Rs86.4 crore in H1 FY22 to Rs63.3 crore in H1 FY23.

On November 12, 2022, the Company also announced bonus issue of 2 shares for every 1 share held, subject to shareholder and other statutory approvals.

At around 9:16 AM, Zim Laboratories was trading at Rs335.25 per share lower by 3.87% on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com

Invest wise with Expert advice



Open Demat Account

Invest wise with Expert advice

By continuing, I accept the Terms & Conditions and agree to receive updates on Whatsapp